RBC Capital Markets Adjusts United Therapeutics Price Target
RBC Capital Markets has lowered its price target for United Therapeutics Corporation from $708 to $697 while maintaining an Outperform rating.
Stocks · News reference
United Therapeutics Receives FDA Clearance for Treprostinil-Iloprost Phase 1 Trial
United Therapeutics Corporation has received FDA clearance to proceed with a Phase 1 clinical trial for its treprostinil-iloprost combination therapy for pulmonary arterial hypertension.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading